KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Assets (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Assets data on record, last reported at $3.0 billion in Q3 2025.

  • For Q3 2025, Assets fell 1.56% year-over-year to $3.0 billion; the TTM value through Sep 2025 reached $3.0 billion, down 1.56%, while the annual FY2024 figure was $3.0 billion, 0.45% changed from the prior year.
  • Assets reached $3.0 billion in Q3 2025 per IONS's latest filing, up from $3.0 billion in the prior quarter.
  • Across five years, Assets topped out at $3.1 billion in Q3 2024 and bottomed at $2.2 billion in Q1 2021.
  • Average Assets over 5 years is $2.7 billion, with a median of $2.8 billion recorded in 2024.
  • Peak YoY movement for Assets: dropped 27.25% in 2021, then rose 21.14% in 2023.
  • A 5-year view of Assets shows it stood at $2.6 billion in 2021, then decreased by 2.98% to $2.5 billion in 2022, then grew by 18.0% to $3.0 billion in 2023, then rose by 0.45% to $3.0 billion in 2024, then increased by 0.98% to $3.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $3.0 billion in Q3 2025, $3.0 billion in Q2 2025, and $2.8 billion in Q1 2025.